QUOTE AND NEWS
Marketwire  Nov 23  Comment 
BUFFALO, NY -- (Marketwire) -- 11/23/09 -- Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced the opening of enrollment for the second human safety study for CBLB502, a drug under development for the treatment of Acute Radiation Syndrome (ARS).
Marketwire  Nov 18  Comment 
BUFFALO, NY -- (Marketwire) -- 11/18/09 -- Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that a breakthrough discovery into the mechanism of action of the Company's first generation Curaxin anticancer compounds was published in an
Marketwire  Nov 2  Comment 
BUFFALO, NY -- (Marketwire) -- 11/02/09 -- Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that the Company is scheduled to present at the Merriman Curhan Ford 6th Annual Investor Summit, November 10, in New York City. Michael Fonstein, Ph.D.,
Marketwire  Oct 20  Comment 
BUFFALO, NY -- (Marketwire) -- 10/20/09 -- Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that the Company will host a roundtable event to discuss Protectan CBLB502, a compound under development for Acute Radiation Syndrome. The roundtable
Marketwire  Oct 19  Comment 
BUFFALO, NY -- (Marketwire) -- 10/19/09 -- Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that the Company is scheduled to present at the 2009 BIO Investor Forum, October 28-29, in San Francisco. Michael Fonstein, Ph.D., Chief Executive
Marketwire  Oct 6  Comment 
BUFFALO, NY -- (Marketwire) -- 10/06/09 -- Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that the Chemical Biological Medical Systems Medical Identification and Treatment Systems Joint Program Executive Office (CBMS-MITS JPEO) of The
Marketwire  Oct 5  Comment 
BUFFALO, NY -- (Marketwire) -- 10/05/09 -- Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced today that Simos Simeonidis, Ph.D., Senior Biotechnology Analyst at Rodman & Renshaw, LLC, has initiated coverage on the Company. The Rodman & Renshaw
StreetInsider.com  Sep 30  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/AFRRI+and+Cleveland+BioLabs+%28CBLI%29+Awarded+%24612K+Grant/4981104.html for the full story.
Marketwire  Sep 30  Comment 
BUFFALO, NY -- (Marketwire) -- 09/30/09 -- Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that the Joint Science and Technology Office for Chemical and Biological Defense at the Defense Threat Reduction Agency of the Department of Defense
Marketwire  Sep 29  Comment 
BUFFALO, NY -- (Marketwire) -- 09/29/09 -- Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that it has been awarded a $5.3 million Grand Opportunities (GO) grant under the American Recovery and Reinvestment Act of 2009 from the Office of the
Suggest a News Source
Topic
Top news source/blog that we're missing
Why do you recommend this news source?
Close 
Thanks for your suggestion!
 
RELATED WIKI ARTICLES

Related Articles

 
TOP CONTRIBUTORS
CBLI AT A GLANCE
P/E -4.30 
EV/EBITDA -4.50 
ROA -256.8%VERY LOW
ROE -4508.5%VERY LOW
Debt to Equity -1.68 
Current Ratio 0.303VERY LOW
Interest Coverage Ratio -9KVERY LOW
 
 
 
 
 
 
 
 

Founded in 2003, Cleveland BioLabs Inc. (CBLI) is a specialized pharmaceutical company involved in the discovery, development, and commercialization of products for cancer treatment and protection of normal tissues from exposure to radiation and other stresses. The company's proprietary technology platform is based on the ability to suppress or stimulate a basic cell defense mechanism called apoptosis, or programmed cell death. Cleveland's drugs can switch apoptosis on and off by affecting key regulators of cell response to stresses, such as radiation or ischemia.

Cleveland has a collaboration agreement with Cleveland Clinic Foundation to use Cleveland Clinic's research base underlying the company's therapeutic platform strategic research partnership with Roswell Park Cancer Institute to develop its cancer and radioprotectant drug candidates and strategic partnership with ChemBridge Corporation to access a chemical library of 214,000 compounds and jointly manage the development and commercialization of compounds arising from selected projects. The company is headquartered in Buffalo, New York and had 35 employees as of December 31, 2006.




References

Wikinvest © 2006, 2007, 2008, 2009. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki